強
強気
強気 · 25%NVAX
$12.67
シナリオ価格
$9.400
-0.290 (-3.09%)終値時点
Loading chart…
- 高値
- 9.880
- 始値
- 9.560
- 出来高加重平均価格
- 9.51
- 出来高
- 4.94M
- 時価総額
- 1.89B
- 安値
- 9.260
- 売買代金
- 47.01M
- EV/EBITDA（TTM）
- -7.03
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
AI分析 of Novavax Inc (NVAX)
中立Novavax Inc is not a strong buy at the moment due to recent performance trends and analyst ratings. The current price is $9.70, which is significantly below the analyst price targets of $8 to $9. The stock has a low RSI of 26.79, indicating it is oversold, but the negative momentum and recent 5-day change of -13.85% suggest caution. The main risk is the forward P/E of 2.58, which indicates potential undervaluation but also reflects uncertainty about future earnings.
アナリスト評価（7）
上値余地 +11.70%
中立
2 買い
5 中立
0 売り
現在: 9.40
安値
6.00
平均
10.50
高値
18.00
BofA
アンダーパフォーム
$8
2026-10-09
BofA
2026-10-09
目標株価
$8
アンダーパフォーム
TD Cowen
中立
$9
2026-05-06
TD Cowen
2026-05-06
目標株価
$9
中立
B. Riley
買い
$18
2026-04-09
B. Riley
2026-04-09
目標株価
$18
買い
BofA
アンダーパフォーム
$8
2026-02-27
BofA
2026-02-27
目標株価
$8
アンダーパフォーム
H.C. Wainwright
買い
$16
2026-02-27
H.C. Wainwright
2026-02-27
目標株価
$16
買い
バリュエーション指標
Novavax Inc（NVAX）の現在の予想PERは2.58で、5年平均は-3.99です。
Alphio AI による NVAX の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
NVAX を保有するクジラ
イベントタイムライン
ニュース
8.510-10stocktwitsNational Cancer Vaccine Initiative Launches
5.010-06CNBCGrail's Cancer Blood Test Approaches Regulatory Decision
2.010-06CNBCTech Stocks Volatility and Investment Outlook
2.010-06stocktwitsRussian Plague Scare Triggers Vaccine Stock Surge
4.510-06stocktwitsTech Stocks Surge, Nasdaq Hits All-Time High
NVAX のよくある質問 — Alphio AI が回答
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Novavax Inc is not a strong buy at the moment due to recent performance trends and analyst ratings. The current price is $9.70, which is significantly below the analyst price targets of $8 to $9. The stock has a low RSI of 26.79, indicating it is oversold, but the negative momentum and recent 5-day change of -13.85% suggest caution. The main risk is the forward P/E of 2.58, which indicates potential undervaluation but also reflects uncertainty about future earnings.
7 analysts cover NVAX: 2 rate it Buy, 5 Hold and 0 Sell. The average price target is 10.50.
コミュニティ
もっと見る ↗
$NVAX The week ultimately closed with a fantastic weekly candle. You can see the nearest resistance levels on the chart. I am including the quarterly SMA20 because it is a key target to reach (it's a pity that it is in freefall, blame the math). Keep an eye on that weekly stochastic over the coming weeks. It looks good for now; let's hope it stays that way. GLTA (Warning: If you don't have a position here at this point, don't start one)
もっと見る
$NVAX Early weekly chart just to show how the week started ... but what really matters is how the week ends. Three things: - The quarterly SMA20 that I mentioned in the prior post is now around 14.3x. - 61.80% fibo retracement was reached ( $13.14 ) - If we want a serious technical move this beast should respect any re-test of the long term resistance recently broken by turning it into support. Otherwise this would be another pump and dump. See you on weekend...
もっと見る
$NVAX That short-term hypothesis was overruled, of course. For what it's worth, the daily RSI is in overbought territory and at its highest level in the last 2 years. If you want this sharp price action to keep going up, then the RSI needs to go wild from here (like in May-June 2024). Good luck to all.
もっと見る
$NVAX Novavax, the maker of a protein-based COVID-19 vaccine, rose Monday as traders circulated claims of a Russian plague outbreak. A lab leak in Siberia sent one technician to the hospital last week, where she died from undetermined pneumonia. The numbers behind the move and what the market has to price next:
もっと見る
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。